Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Nokia, DOCOMO and NTT make two key 6G advances #MWC23

Published

on

<!– Name:DistributionId Value:1000782688 –> <!– Name:NewsArchiveTags Value:2050 –> <!– Name:NewsArchiveOrgTags Value:1#5G;2#ESG;3#Innovation;4#Industry;5#New products and services;6#Partners and customers;7#Patents and licensing;5417#Flagging announcements;2113#Lehdistötiedotteet;5416#Liputusilmoitukset;7674#Managers Transactions;2050#Press Releases;2116#Pörssitiedotteet;2053#Stock Exchange Releases;2054#News Digest;2055#Repurchase of own shares –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:9578 –> <!– Name:CustomerId Value:1011615 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:63ba7a71-aaad-4ee6-8727-3e4fb5b89bdf –>

Press Release

Nokia, DOCOMO and NTT make two key 6G advances #MWC23

  • The AI-native air interface will give radios the ability to learn.
  • Sub-terahertz spectrum will open up enormous capacity to future 6G networks.

15 February 2023

Espoo, Finland – Nokia, NTT DOCOMO, INC. and NTT today announced that they have achieved two key technological milestones on the path to 6G. The first is the implementation of artificial intelligence (AI) and machine learning (ML) into the radio air interface, effectively giving 6G radios the ability to learn. The second is the utilization of new sub-terahertz (sub-THz) spectrum to dramatically boost network capacity.

The AI-native air interface and sub-THz spectrum are both critical research topics that Nokia, DOCOMO and NTT are exploring for future 6G networks. These technologies could pave the way for new immersive metaverse and extended reality (XR) experiences and a new generation of mobile applications. The companies have implemented both technologies as proofs of concept at Nokia Bell Labs in Stuttgart, Germany, and Nokia and DOCOMO will demonstrate both technologies at Mobile World Congress in Barcelona, Feb. 27 – March 2.

By pairing a AI-based learned waveform in a transmitter with a deep-learning receiver, Nokia Bell Labs, DOCOMO and NTT researchers were able to design and implement a learning air interface that transmits data efficiently under many different scenarios. This AI/ML-based implementation significantly reduces signaling overhead, producing up to a 30% improvement in throughput.

In addition, the AI-native air interface will grant 6G networks the flexibility to adapt to the type of connection demanded by an application, device or user. For instance, a network in a factory can be optimized for industrial sensors at one moment and then reconfigured for robotic systems or video surveillance. In the public network, an AI-enhanced network can provide an optimized connection for a pedestrian in an XR session as well as an emergency vehicle traveling at high speed.

The sub-THz bands (100GHz and above) have never been designated for cellular use because of their propagation characteristics, but new techniques such as beamforming could open up those frequencies to future 6G networks. These higher frequencies are well suited for high-accuracy radio sensing, which will likely be another key feature of 6G. In their proof-of-concept, Nokia, DOCOMO and NTT were able to demonstrate a 25 Gbps connection on a single 256QAM stream over a carrier frequency of 144 GHz using beamforming. Accessing the sub-THz bands would inject enormous capacity into 6G networks. The sub-THz bands won’t just improve overall capacity, they will allow 6G networks to support the most bandwidth intensive future use cases requiring multi-gigabit average connections.

Nokia, DOCOMO and NTT first launched their 6G collaboration in June, 2022, with the aim of jointly defining and developing key technologies for the next generation of networking. The collaboration continues a long history of pioneering between DOCOMO and Nokia. Starting with 3G in the 1990s, to 4G, and to today’s 5G including collaboration in 5G O-RAN, the companies have turned ideas into implementations and pushed boundaries to create optimized experiences for end users.

Takehiro Nakamura, Chief Technology Architect, DOCOMO, said: “We are delighted to announce the steady progress of two key technologies toward 6G as achievements of the collaboration with NTT and Nokia started in June 2022. Through the collaboration, we continue to establish innovative 6G technologies and contribute to the global standardization and commercialization of 6G.”

Peter Vetter, President of Bell Labs Core Research, Nokia, said: “For the 6G era, we are using communication as a starting point. Networks will think, sense and act, and they will become the nexus point that bridges our digital and physical realities. DOCOMO and NTT share our 6G vision, and together we’re doing the fundamental research that will breath life into that future.”

Nokia believes 6G will not just build on existing technologies and systems but expand and transform what a network can do. It will fuse the human, physical and digital worlds to liberate our innate human potential. To achieve this, Nokia has envisioned six key technologies that will be vital components of future 6G networks. These include spectrum technologies; AI native air interface; network as a sensor; extreme connectivity, cognitive, automated and specialized architectures; and security and trust.

Meet us at Mobile World Congress 2023 #MWC23 www.nokia.com/mwc    

Follow us on Twitter, LinkedIn, Instagram, Facebook and TikTok

About Nokia
At Nokia, we create technology that helps the world act together.

As a trusted partner for critical networks, we are committed to innovation and technology leadership across mobile, fixed and cloud networks. We create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs.

Adhering to high standards of integrity and security, we help build the capabilities needed for a more productive, sustainable and inclusive world.

Media Inquiries:
Nokia
Communications
Email: [email protected]

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Ancoris Recognised as Top Place to Work for Second Year Running by The Sunday Times

Published

on

ancoris-recognised-as-top-place-to-work-for-second-year-running-by-the-sunday-times

Ancoris recognised for fostering a sense of empowerment and respect within the workplace91% of Ancoris employees feel empowered at work93% of employees say that are treated with respectLONDON, May 21, 2024 /PRNewswire/ — Ancoris, a UK-based Google Cloud services provider, has been named a Top Medium Business in The Sunday Times 2024 Best Places to Work list. The accolade has been awarded for the second year in a row, and recognises Ancoris’ focus on DEI; its commitment to empowerment, reward, and recognition; and its wellbeing policies and frameworks.

“I am so pleased to see Ancoris recognised, once again, as a top place to work!” says Andre Azevedo, Ancoris CEO. “Ancoris is a place where we try our best to foster collaboration, empowerment, innovation, and respect – so to have our employees echo this and respond in the way they have is amazing.”
The Sunday Times survey captured Ancoris employees’ responses in a number of categories: Reward and Recognition, Information Sharing, Empowerment, Wellbeing, Instilling Pride, and Job Satisfaction. The independently managed survey showed Ancoris scoring “excellent” across all six engagement categories, with top scores in Empowerment, Wellbeing, Reward & Recognition. In response, 93% of employees say they are treated with respect; 92% feel trusted and able to make decisions; and 91% of employees feel empowered at work.
“We’ve seen a lot of change over the last 12 months. The rise of Generative AI has caused shifts in our market and  economic conditions are causing customers to really qualify where they make technology investments. These pivots undoubtedly have an impact on our employees and how people feel at work,” Azevedo continues. “I truly believe, however, the innovative work we are doing for our customers has helped us maintain and create an even stronger sense of collaboration and pride for our team members. We’re lucky to have so many smart people within our business, so continuing to give them interesting, challenging, and rewarding problems to solve for our customers is really key.”
About AncorisAncoris is a leading Google Cloud Services Provider, headquartered in the UK, on a mission to become the most innovative Google Cloud partner in the ecosystem. Ancoris leverages its strong problem solving skills and continuous improvement approach to help customers become AI Native and stay ahead of their competition. Ancoris has extensive experience in Google Cloud technologies helping enterprises integrate AI-native solutions into their business through expertise in Data & AI, Application and Infrastructure Modernisation, Workspace, and Maps. Ancoris was recognized as a Rising Star for Data, Analytics, and Machine Learning in the ISG Provider™ Lens for Google Cloud Partner Ecosystem in 2022 and 2023 consecutively, and awarded Google Cloud’s 2024 EMEA Public Sector Partner of the Year award. Ancoris employs the best in the business and was named in the Top 10 Sunday Times Best Places to Work 2023, and a Top Place to Work in 2024.
Contact: Holly [email protected]
Photo – https://mma.prnewswire.com/media/2417995/Ancoris_Sunday_Times.jpgLogo – https://mma.prnewswire.com/media/2099949/4717512/Ancoris_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ancoris-recognised-as-top-place-to-work-for-second-year-running-by-the-sunday-times-302151325.html

Continue Reading

Artificial Intelligence

Department of Health – Abu Dhabi Partners with Roche Pharmaceuticals Middle East to Elevate Research, Clinical Trials, and Real-World Data

Published

on

department-of-health-–-abu-dhabi-partners-with-roche-pharmaceuticals-middle-east-to-elevate-research,-clinical-trials,-and-real-world-data

ABU DHABI, UAE, May 21, 2024 /PRNewswire/ — The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with Roche Pharmaceuticals Middle East during Abu Dhabi Global Healthcare Week (ADGHW). Under the MoU, the two entities will advance critical research using real-world data to study and assess the spinal muscular atrophy burden in Abu Dhabi, as well as assessing potential conduction of research and the facilitation of real-world data collection to monitor Duchenne Muscular Dystrophy (DMD) disease.

 
 
In the presence of Dr. Rashed Alsuwaidi, the Executive Director of the Healthcare Workforce Planning Sector at DoH and Michael Oberreiter, Head of Global Access at Roche Pharmaceuticals, the MoU was signed by Dr. Asma Al Mannaei, the Executive Director of the Research and Innovation Centre at DoH and Mohamed Elshaarawy, General Manager Roche Pharmaceuticals, UAE.
Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Center at the at DoH said: “Abu Dhabi has a track record of excellence and fast-growing, future-forward, data-enabled services. Serving as a hub for healthcare data, Abu Dhabi’s substantial computing power enables it to harness the potential within this data, transforming it into valuable information. This, in turn, allows us to innovate and develop novel approaches to shift healthcare towards prediction, prevention, and treatment, thereby accelerating the future of healthcare, not only for Abu Dhabi but for the global community. Through international collaborations, Abu Dhabi seeks to lead research groups supported by global partners to explore the resilience and sustainability of the healthcare sector worldwide as well as expand access to quality care for patients around the world.”
The two entities will work together to support the evolution of real-world data collection frameworks in Abu Dhabi. Enhancing DoH’s ability to track and monitor outcomes of therapies will support DoH in making informed clinical and policy decisions for better optimisation of patient outcomes. Furthermore, DoH and Roche will strengthen the research network across Abu Dhabi and improve accrual for potential clinical trials.
Mohamed Elshaarawy, General Manager Roche Pharmaceuticals, UAE said: “This MoU underscores our collaboration with the DoH which is fuelled by a shared vision of harnessing the power of data to drive informed decision-making within the healthcare system. Data-driven healthcare systems hold immense potential to revolutionise patient care and outcomes. Through the generation, utilisation, and realisation of data, healthcare professionals and policymakers can unlock valuable insights, identify trends, and make evidence-based decisions. This data-driven approach enables us to optimise resource allocation, personalise treatment approaches, and ultimately achieve better patient outcomes. By harnessing the full potential of data, we can improve the overall efficiency and effectiveness of the healthcare system, ensuring that every patient receives the highest quality of care tailored to their specific needs. We are sincerely grateful for the trust, confidence, and empowerment the DoH has placed in establishing this effective public-private partnership with Roche in the UAE.”
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of Abu Dhabi Executive Council, ADGHW is a major government initiative by the DoH, which took place from the 13th -15th May 2024.
For more information please visit: https://www.adghw.com/
About Department of Health – Abu Dhabi (DoH):
The DoH is the regulatory body of the healthcare sector at the Emirate of Abu Dhabi and ensures excellence in healthcare by monitoring the health status of the population. DoH defines the strategy for the health system, monitors and analyses the health status of the population and performance of the system. In addition, DoH shapes the regulatory framework for the health system, inspects against regulations, enforce standards, and encourages adoption of world-class best practices and performance targets by all healthcare service providers in the Emirate. DoH also drives programmes to increase awareness and adoption of healthy living standards among the residents of the Emirate of Abu Dhabi in addition to regulating scope of services, premiums and reimbursement rates of the health system.
For further information on DoH, visit https://www.doh.gov.ae/ and follow on X, Instagram, Facebook, LinkedIn and YouTube.
Photo – https://mma.prnewswire.com/media/2417975/DoH_Partners_with_Roche_Pharmaceuticals.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/department-of-health–abu-dhabi-partners-with-roche-pharmaceuticals-middle-east-to-elevate-research-clinical-trials-and-real-world-data-302151316.html

Continue Reading

Artificial Intelligence

Biopharma Leaders Shape the Future of Drug Development at Veeva R&D and Quality Summit Europe

Published

on

biopharma-leaders-shape-the-future-of-drug-development-at-veeva-r&d-and-quality-summit-europe

Ascendis, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva to keynote sharing innovations to drive better patient outcomes
BARCELONA, Spain, May 21, 2024 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that leaders from Ascendis Pharma A/S, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva will be keynote speakers at Veeva R&D and Quality Summit, Europe, June 4-5 in Madrid, Spain. Life sciences professionals across the industry will come together to share how connected technologies across clinical, regulatory, safety, and quality are advancing innovations for patients.

As one of the largest gatherings of biopharma leaders in Europe, Veeva R&D and Quality Summit will bring together over 1,000 industry professionals to share learnings across more than 100 sessions. Bayer and Jazz Pharmaceuticals will join Rik Van Mol, senior vice president of Veeva Development Cloud, and Avril England, general manager of Veeva Vault, for the opening keynote to explore the future of development for new medicines and therapies.
The event’s zone keynotes include:
Ascendis and Bayer, sharing strategies to reduce costs and accelerate trials with a connected platform.Boehringer Ingelheim, detailing its shift toward data-centric regulatory information management.Novo Nordisk, showing how it uses data and AI to transform clinical research.Sanofi, explaining its innovative approach to advance quality through operational excellence.Teva, providing insight into its rapid journey from disparate safety systems into one streamlined global solution.A panel with Elpida Therapeutics CEO Terry Pirovolakis and Veeva experts will close the event with a discussion on how the industry can best accelerate the development of life-saving rare disease gene therapies.
“Connecting clinical, regulatory, safety, and quality is key to advancing the product lifecycle and delivering better outcomes for patients,” says Rik Van Mol, senior vice president of Veeva Development Cloud. “At Veeva R&D and Quality Summit, biopharma leaders can connect, exchange ideas, and share new strategies to advance the industry forward together.”
Veeva R&D and Quality Summit is open exclusively to life sciences professionals. Register and review the agenda at veeva.com/eu/Summit.
Additional InformationConnect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Jeremy WhittakerVeeva [email protected]
Logo – https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/biopharma-leaders-shape-the-future-of-drug-development-at-veeva-rd-and-quality-summit-europe-302150491.html

Continue Reading

Trending